Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
DREAM
The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
1 other identifier
observational
700
8 countries
81
Brief Summary
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice. Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide. Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2025
Typical duration for all trials
81 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 18, 2025
CompletedFirst Posted
Study publicly available on registry
June 26, 2025
CompletedStudy Start
First participant enrolled
September 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
July 8, 2026
July 1, 2026
2.5 years
June 18, 2025
July 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1
DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 (no at all) to 1 (a little).
At 12 months
Study Arms (1)
Risankizumab
Participants will receive risankizumab as prescribed by their physician according to local label.
Eligibility Criteria
Adult participants with moderate to severe plaque psoriasis who are prescribed risankizumab by their physician.
You may qualify if:
- Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
- Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
- Decision to treat with risankizumab is made prior to and independently of study participation.
You may not qualify if:
- History of a sleep disorder diagnosis which the patient is currently being treated for.
- Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
- Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (81)
Dermatology Research Institute - Blackfoot Trail /ID# 276722
Calgary, Alberta, T2J 7E1, Canada
Rejuvenation Dermatology - Edmonton Downtown /ID# 276688
Edmonton, Alberta, T5J 3S9, Canada
Winnipeg Clinic /ID# 276751
Winnipeg, Manitoba, R3C 1T6, Canada
Wiseman Dermatology Research /ID# 276847
Winnipeg, Manitoba, R3M 3Z4, Canada
Cca Medical Research /ID# 276944
Ajax, Ontario, L1S 7K8, Canada
Quinte dermatology /ID# 277497
Belleville, Ontario, K8N 2S9, Canada
Dermatrials Research /ID# 276714
Hamilton, Ontario, L8N 1Y2, Canada
Lovegrove Dermatology /ID# 276797
London, Ontario, N6A 5R9, Canada
Lynderm Research Inc /ID# 276755
Markham, Ontario, L3P 1X2, Canada
Rejuvenation Dermatology Clinic Oakville /ID# 277492
Oakville, Ontario, L6H 6P8, Canada
JRB Research inc. /ID# 277730
Ottawa, Ontario, K1K 4L2, Canada
Factor Dermatology /ID# 278610
Ottawa, Ontario, K2A 2M3, Canada
SKiN Centre for Dermatology /ID# 277594
Peterborough, Ontario, K9J 5K2, Canada
Eternal Springtime Dermatology /ID# 278598
Thunder Bay, Ontario, P7C 4Y7, Canada
North York Research /ID# 276835
Toronto, Ontario, M2N 3A6, Canada
Toronto Dermatology Centre /ID# 276846
Toronto, Ontario, M3H 5Y8, Canada
Centre for Medical and Surgical Dermatology /ID# 278775
Whitby, Ontario, L1N 8M7, Canada
Dre Angelique Gagne-Henley M.D. inc. /ID# 276687
Saint-Jérôme, Quebec, J7Z 7E2, Canada
Fakultní Nemocnice U Sv. Anny V Brně /ID# 275799
Brno, Brno-mesto, 656 91, Czechia
Fakultni nemocnice Bulovka /ID# 275540
Prague, Central Bohemia, 180 81, Czechia
Dermafit Centrum /ID# 275897
Pilsen, Plzeň Region, 323 00, Czechia
Dermamedest /ID# 275898
Prague, Praha 2, 120 00, Czechia
Nemocnice Ceske Budejovice /ID# 275541
České Budějovice, 370 01, Czechia
Fakultni nemocnice Kralovske Vinohrady /ID# 275800
Prague, 100 34, Czechia
Chu de Dijon /ID# 279900
Dijon, Bourgogne-Franche-Comté, 21000, France
Centre Hospitalier de Niort Georges Renon /ID# 279604
Niort, Deux-Sevres, 79021, France
Dr. Rima Mohty /ID# 279951
Beauvais, Oise, 60000, France
Centre Hospitalier Du Mans /ID# 279899
Le Mans, Sarthe, 72037, France
Hopital d'Instruction des Armees Sainte-Anne /ID# 278106
Toulon, Var, 83800, France
Hôpitaux Drôme Nord - Romans /ID# 278109
Romans-sur-Isère, 26102, France
Dr. med. Moritz Huber und Dr. med. Martin Heister /ID# 277627
Friedrichshafen, Baden-Wurttemberg, 88046, Germany
Dermakulm /Id# 277864
Kulmbach, Bavaria, 95326, Germany
Dermazent /Id# 280327
Munich, Bavaria, 80331, Germany
Hautaerzte am Nauener Tor /ID# 284579
Potsdam, Brandenburg, 14469, Germany
Universitaetsmedizin Mainz /ID# 278229
Mainz, Rhineland-Palatinate, 55131, Germany
Dermatologie Moelln Praxis Dr. Bodo Segert /ID# 277628
Mölln, Schleswig-Holstein, 23879, Germany
Universitaetsklinikum Hamburg-Eppendorf /ID# 277164
Hamburg, 20246, Germany
Cutaneum /ID# 277294
Hamburg, 20249, Germany
Private Practice - Dr. Mario Pawlak /ID# 277465
Heilbad Heiligenstadt, 37308, Germany
Hautarztpraxis Dr. Med. Ulrike Wiemers / Dr. Med. Franca Wiemers /ID# 277821
Leipzig, 04317, Germany
Hautarztpraxis Schwelm /ID# 277464
Schwelm, 58332, Germany
General Hospital Andreas Syggros /ID# 276826
Athens, Attica, 16121, Greece
General Hospital Andreas Syggros /ID# 279246
Athens, Attica, 16121, Greece
University General Hospital Attikon /ID# 278389
Chaïdári, Attica, 12462, Greece
Tzaneio Prefecture General Hospital of Piraeus /ID# 276532
Piraeus, Attica, 18536, Greece
Asklipieio General Hospital of Voula /ID# 278235
Voula, Attica, 16673, Greece
The University Hospital of Larissa /ID# 276576
Larissa, Thessaly, 41110, Greece
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 276488
Thessaloniki, 54643, Greece
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 276489
Thessaloniki, 54643, Greece
Papageorgiou General Hospital /ID# 276487
Thessaloniki, 56429, Greece
ASL 1 Abruzzo - Ospedale regionale San Salvatore /ID# 277341
L’Aquila, L Aquila, 67100, Italy
IRCCS Ospedale San Raffaele /ID# 277342
Milan, Milano, 20132, Italy
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 277713
Naples, Napoli, 80138, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 278080
Rome, Roma, 00168, Italy
Ospedale San Martino /ID# 278984
Genova, 16132, Italy
Gunma University Hospital /ID# 278497
Maebashi, Gunma, 371-8511, Japan
Asahikawa Medical University Hospital /ID# 278981
Asahikawa-shi, Hokkaido, 078-8510, Japan
Hokkaido University Hospital /ID# 278260
Sapporo, Hokkaido, 060-8648, Japan
Hosui General Medical Clinic /ID# 279520
Sapporo, Hokkaido, 0640807, Japan
Kagoshima University Hospital /ID# 278514
Kagoshima, Kagoshima-ken, 890-8520, Japan
Tokai University Hospital /ID# 278294
Isehara, Kanagawa, 259-1193, Japan
Yokohama City University Hospital /ID# 278257
Yokohama, Kanagawa, 236-0004, Japan
University Hospital Kyoto Prefectural University of Medicine /ID# 278962
Kyoto, Kyoto, 602-8566, Japan
Kawasaki Medical School Hospital /ID# 278259
Kurashiki, Okayama-ken, 701-0192, Japan
University of the Ryukyus Hospital /ID# 278256
Ginowan-shi, Okinawa, 901-2725, Japan
Kindai University Hospital /ID# 278258
Sakai-shi, Osaka, 590-0197, Japan
The University of Osaka Hospital /ID# 278436
Suita-shi, Osaka, 565-0871, Japan
Juntendo University Hospital /ID# 278495
Bunkyo-ku, Tokyo, 113-8431, Japan
Seibo Hospital /ID# 279522
Shinjuku-ku, Tokyo, 161-8521, Japan
Fukuoka University Hospital /ID# 278600
Fukuoka, 814-0180, Japan
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 278434
Osaka, 550-0006, Japan
Tokyo Yamate Medical Center /ID# 278960
Tokyo, 169-0073, Japan
Teikyo University Hospital /ID# 278228
Tokyo, 173-8605, Japan
Nihon University Itabashi Hospital /ID# 279916
Tokyo, 173-8610, Japan
Hospital Regional Universitario de Malaga /ID# 277220
Málaga, Andalusia, 29010, Spain
Hospital Universitario de León /ID# 277895
León, Leon, 24080, Spain
Hospital General Universitario Santa María Del Rosell /ID# 277894
Cartagena, Murcia, 30203, Spain
Hospital Clínico Universitario Virgen de la Arrixaca /ID# 283338
El Palmar, Murcia, 30120, Spain
Hospital General Universitario Morales Meseguer /ID# 283339
Murcia, 30008, Spain
Complejo Hospitalario Universitario de Pontevedra /ID# 278085
Pontevedra, 36071, Spain
Hospital Universitario De Toledo /ID# 277896
Toledo, 45007, Spain
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2025
First Posted
June 26, 2025
Study Start
September 9, 2025
Primary Completion (Estimated)
March 1, 2028
Study Completion (Estimated)
March 1, 2028
Last Updated
July 8, 2026
Record last verified: 2026-07